Amgen (NASDAQ:AMGN) Announces Earnings Results, Beats Expectations By $0.74 EPS

Key Points

• Amgen reported earnings of $6.02 EPS for the quarter, exceeding analysts' estimates of $5.21 by $0.81.
• The company updated its FY 2025 guidance to $20.200-21.300 EPS while announcing a quarterly dividend of $2.38 per share, reflecting a 3.2% dividend yield.
• Amgen's stock decreased by 0.6% to $300.08, with a recent consensus rating of "Hold" and a target price of $307.27 from analysts.

Amgen (NASDAQ:AMGN - Get Free Report) announced its quarterly earnings data on Tuesday. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74, Zacks reports. Amgen had a return on equity of 174.71% and a net margin of 18.96%. The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the company earned $4.97 earnings per share. Amgen's quarterly revenue was up 9.4% on a year-over-year basis. Amgen updated its FY 2025 guidance to 20.200-21.300 EPS.

Amgen Stock Up 1.2%

NASDAQ:AMGN traded up $3.53 during trading hours on Friday, hitting $288.23. 1,802,960 shares of the stock traded hands, compared to its average volume of 2,050,777. The firm has a 50 day moving average price of $293.23 and a 200 day moving average price of $292.57. The company has a current ratio of 1.31, a quick ratio of 0.88 and a debt-to-equity ratio of 7.24. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $339.17. The firm has a market cap of $155.17 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 2.44 and a beta of 0.49.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Friday, August 22nd. Amgen's payout ratio is 77.84%.

Wall Street Analyst Weigh In

A number of brokerages have commented on AMGN. Piper Sandler restated an "overweight" rating and issued a $328.00 target price on shares of Amgen in a research note on Friday, June 27th. Erste Group Bank downgraded Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Guggenheim initiated coverage on Amgen in a research report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective for the company. William Blair reiterated an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. Finally, Mizuho boosted their price objective on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Amgen has an average rating of "Hold" and a consensus target price of $303.76.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the sale, the senior vice president directly owned 8,162 shares of the company's stock, valued at $2,364,368.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.76% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Amgen

An institutional investor recently raised its position in Amgen stock. Brighton Jones LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 23.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,468 shares of the medical research company's stock after acquiring an additional 5,226 shares during the quarter. Brighton Jones LLC's holdings in Amgen were worth $7,159,000 as of its most recent filing with the Securities and Exchange Commission. 76.50% of the stock is currently owned by institutional investors.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.